SUBSCRIBE
SUBSCRIBE

Alkermes

NEWS
Policy
FDA Eyes Safety Of Popular Anemia Drugs
October 19, 2005
 · 
1 min read
Business
ConjuChem
October 19, 2005
 · 
8 min read
Biotech Moves Ahead Of Major Indexes
October 19, 2005
 · 
1 min read
Load More
JOBS
IN THE PRESS
Press Releases
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
January 6, 2026
 · 
5 min read
Press Releases
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 30, 2025
 · 
1 min read
Press Releases
Alkermes to Participate in Two Upcoming December 2025 Investor Conferences
November 26, 2025
 · 
1 min read
Press Releases
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
November 13, 2025
 · 
11 min read
Press Releases
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1
July 21, 2025
 · 
11 min read
Press Releases
Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024
September 23, 2024
 · 
9 min read
Drug Development
Journal of Clinical Psychiatry Publishes Data from Alkermes’ ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in Their Illness
March 23, 2023
 · 
15 min read
Alkermes to Participate in the Stifel 2023 CNS Days
March 15, 2023
 · 
1 min read
Business
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023
February 16, 2023
 · 
23 min read
Business
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023
February 9, 2023
 · 
1 min read
Load More